Notice of NICHD's Participation in PA-18-939 "Research on Chronic Overlapping Pain Conditions (R21 Clinical Trial Not Allowed)

Notice Number: NOT-HD-18-025

Key Dates
Release Date: November 7, 2018

Related Announcements
PA-18-939

Issued by
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Purpose

The purpose of this Notice is to inform potential applicants that the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) will participate, effective immediately, in PA-18-939, “Research on Chronic Overlapping Pain Conditions (R21 Clinical Trial Not Allowed)".

Part 1. Overview Information

Components of Participating Organizations

National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Alcohol Abuse and Alcoholism (NIAAA )
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute of Dental and Craniofacial Research (NIDCR)
National Institute of Nursing Research (NINR)
National Center for Complementary and Integrative Health (NCCIH)
Office of Behavioral and Social Sciences Research (OBSSR)
Office of Research on Women's Health (ORWH)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.853, 93.273, 83.846, 83.361, 93.213, 93.313, 93.121, 93.865

Part 2. Section VII. Agency Contacts

Scientific/Research Contact(s)
Susan Marden PhD RN
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Telephone: 301-435-6838

Email: [email protected]

Financial/Grants Management Contact(s)
Bryan S. Clark, MBA
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Telephone: 301-435-6975
Email: [email protected]

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Susan Marden PhD RN
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Telephone: 301-435-6838
Email: [email protected]